Aims: Diabetes mellitus (DM) is a multifaceted metabolic disorder characterized by chronic hyperglycaemia due to impairments in insulin secretion, insulin action, or both. Traditional management approaches often fail to address the heterogeneous nature of DM, leading to suboptimal outcomes. Biomarkers have emerged as essential tools for stratifying patients and guiding personalized treatment strategies. This study analyses selected diabetes cases and explores the role of biomarkers in designing individualized therapies. Key findings demonstrate improved glycaemic control, reduced cardiovascular risks, and enhanced patient outcomes through biomarker-guided interventions. We can conclude from this study and the results on the crucial role of medicine in the follow-up of diabetic patients. Study design: Samples were collected from different hospitals in Diyala Governorate (Baquba Teaching Hospital- Diyala, Al-Zahraa Hospital- Shahraban and Al-Khalis Hospital- Khalis) and it took 10 months to collect samples. Methodology: The study included 90 patients with diabetes (T1DM, T2DM, and gestational diabetes). Their ages ranged from 25 to 70 years. The male-female ratio was 38/52. The ratio of t T2DM diabetes was 47/90, T1DM diabetes 17/90, and gestational diabetes 26/90. Results: The results show that personalized biomarker-based therapies significantly improve blood sugar control, reduce systemic inflammation, and reduce cardiovascular risk in patients with diabetes. By tailoring treatment plans based on individual profiles, physicians are able to achieve better overall outcomes, highlighting the potential of precision medicine in diabetes management. Conclusion: The study concludes by emphasizing the critical role of personalized medicine in improving treatment efficacy, reducing side effects, and improving patient outcomes.
Ali Metalli -Sabah (Tue,) studied this question.